A radio show features a Stanford oncologist discussing ultra-fast "flash" radiation therapy, which may kill cancer cells with less collateral damage.
The prevalence of genetic testing in the United States falls short of the recommended guidelines for women with ovarian cancer, new research indicates.
Study finds that starting colorectal cancer screening at age 45 would avert deaths, but testing more older people would be more beneficial.
A push to personalize medicine can backfire when it comes to screening for colorectal cancer, says a Stanford gastroenterologist.
Editors note: The family has requested removing the video to protect their daughter's privacy. We apologize for the inconvenience.
Scientists have modified immune cells, imbuing them with the ability to not only detect, but reveal, the presence of a tumor.
Stanford researchers make progress in predicting which patients will suffer heart problems from chemotherapy, and may have found a drug to mitigate them.
Molecular data identifies breast cancer subgroups likely to recur decades after successful treatment, predicts probable timing and location of metastases.
Cru Silva was diagnosed with a type of eye cancer when he was 18 months old. After nearly a year of treatments, he's healthy and back home in Hawaii.
An antibody against the "don't eat me" signal on cancer cells appears safe and well-tolerated by patients with advanced cancers. A phase 2 trial is planned.
Nurse-scientist Kimberly Pyke-Grimm draws on her clinical experience when studying how teens, young adults and families make decisions about cancer care.
Stanford scientists have moved a big step closer toward using engineered immune cells to treat many forms of pediatric cancer.
In this excerpt originally in Months to Years, Michelle Mindlin reflects on how she found courage as she faced cancer repeatedly.
Scientists modify a well-established imaging technique using gold nanoparticles to see swaths of tissue at a single-cell level.
Proteins that guide transcription factors from the nuclear membrane to the DNA cause drug-resistant skin cancers and are new targets for drug development.
A decades-long scientific collaboration points the way to therapies for "chemo brain," the cognitive impairment that follows cancer treatment.
